文献速递肝胆胰外科

大肝癌大范围肝切除前序贯TACE联合PVE与单纯PVE的倾向性分析

Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis.
PubMed 文献 · Surgery · 2019-11-25

该研究纳入2005至2015年55例大肝癌(≥50 mm)拟行大范围肝切除患者,比较序贯TACE联合PVE(n=27)与单纯PVE(n=28)的早期及远期结局。意向性分析显示联合组3年总生存率60% vs 20%(P=.01)、3年无进展生存率35% vs 0%(P<.001),且未来残肝增生更显著(43% vs 31%,P=0.03)。

要点

  • 大肝癌大范围肝切除前序贯TACE联合PVE较单纯PVE改善3年总生存(60% vs 20%)
  • 联合组3年无进展生存率35% vs 0%,切除后仍为28% vs 0%
  • 联合组未来残肝增生更显著(43% vs 31%),最终肝切除比例91% vs 68%

核心结论

  • 大肝癌拟行大范围肝切除患者中,PVE前序贯TACE可增加未来残肝增生程度并改善肿瘤学结局。

研究设计与样本

  • 采用意向性治疗分析比较两组早期及远期结局,两组基线患者与肿瘤特征相似。

主要发现

  • 联合组与单纯PVE组3年总生存率分别为60%与20%(P=.01),3年无进展生存率分别为35%与0%(P<.001)。
  • 联合组最终肝切除比例为91%,单纯PVE组为68%(P=.08)。
  • PVE后未来残肝增生联合组为43%,单纯PVE组为31%(P=0.03)。
  • 切除后联合组3年无进展生存率为28%,单纯PVE组为0%(P=.03)。
  • TACE后降期使4例患者改变初始策略,最终1例肝移植、3例局限肝切除。

关键数值与推荐

  • 大肝癌定义为肿瘤≥50 mm。
  • 联合组3年总生存率60% vs 20%(P=.01),3年无进展生存率35% vs 0%(P<.001)。
  • 未来残肝增生43% vs 31%(P=0.03),最终肝切除比例91% vs 68%(P=.08)。

临床怎么用

  • 对大肝癌拟行大范围肝切除患者,可考虑在PVE前序贯TACE以促进未来残肝增生并改善肿瘤学结局。
  • TACE后降期可能改变初始手术策略,需重新评估肝移植或局限肝切除的可行性。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the value of sequential transcatheter arterial chemoembolization and portal vein embolization compared with portal vein embolization alone before major hepatectomy for large hepatocellular carcinoma. We aimed to compare early and long-term outcomes of these two strategies. METHODS: We included all consecutive patients with large hepatocellular carcinoma (≥50 mm) scheduled for sequential transcatheter arterial chemoembolization and portal vein embolization or portal vein embolization alone before major hepatectomy from January 2005 to December 2015. Comparisons were made on an intent-to-treat basis. RESULTS: A total of 55 patients were included as follows: sequential transcatheter arterial chemoembolization and portal vein embolization (n = 27) and portal vein embolization alone (n = 28). Baseline patient and tumor characteristics were similar in the 2 groups. Downstaging after transcatheter arterial chemoembolization changed the initial strategy in 4 patients who finally underwent liver transplant (n = 1) and limited hepatectomy (n = 3). Overall survival and progression-free survival were better in the transcatheter arterial chemoembolization group compared with the portal vein embolization alone group (3-year overall survival of 60% vs 20%; P = .01 and 3-year progression-free survival of 35% vs 0%; P < .001). The proportion of patients who finally underwent hepatectomy after transcatheter arterial chemoembolization plus portal vein embolization was 91% vs 68% after portal vein embolization alone (P = .08). Hypertrophy of the future remnant liver after portal vein embolization was greater after transcatheter arterial chemoembolization (43% vs 31%, P = 0.03). After resection, the group that received transcatheter arterial chemoembolization and portal vein embolization experienced better progression-free survival compared with portal vein embolization alone (3-year progression-free survival of 28% vs 0%; P = .03). CONCLUSION: Our results suggest that transcatheter arterial chemoembolization before portal vein embolization increases the degree of hypertrophy of the future remnant liver after portal vein embolization and yields improved oncologic outcomes in patients with large hepatocellular carcinomas planned for major hepatectomy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Terasawa M, Allard MA, Golse N, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis. Surgery. 2019. PMID: 31780050. doi:10.1016/j.surg.2019.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。